Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

• Status: Terminated
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genmab
• Treatments: Antibodies, Monoclonal; Zalutumumab

Criteria

Inclusion Criteria:

• Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx

Exclusion Criteria:

• Prior treatment with radiotherapy in the head and neck area

• Prior treatment with chemotherapy

• Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors)

• Previous surgery with curative intent for head and neck cancer